Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonuccelli, U.
Right arrow Articles by Muratorio, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonuccelli, U.
Right arrow Articles by Muratorio, A.
NEUROLOGY 1994;44:821
© 1994 American Academy of Neurology

Clozapine in Huntington's chorea

U. Bonuccelli, MD, R. Ceravolo, MD, C. Maremmani, MD, A. Nuti, MD, G. Rossi, PhD and A. Muratorio, MD

Institute of Clinical Neurology, CNR, Pisa, Italy. (Drs. Bonuccelli, Ceravolo, Maremmani, Nuti, and Muratorio)
University of Pisa, and the Institute of Clinical Physiology and Biostatistics Unit (Dr. Rossi)

Article abstract –In an open-label trial, we evaluated the efficacy of clozapine on abnormal involuntary movements in five patients with Huntington's chorea. We administered clozapine at increasing doses of 25, 50, and 150 mg/d for 3 weeks. Subjective self-evaluation of all patients reported reduction of chorea and improvement of daily living activities. At the end of the trial, all patients requested to continue with clozapine. Objective evaluation with the Abnormal Involuntary Movements Scale demonstrated in all patients moderate-to-marked reduction of abnormal involuntary movements without any significant side effects; the improvement was dose-dependent and markedly decreased 1 week after drug withdrawal

Address correspondence and reprint requests to Dr. Ubaldo Bonuccelli, Institute of Clinical Neurology, University of Pisa, Via Roma 67, 56100 Pisa, Italy.

Received August 24, 1993. Accepted for publication in final form November 2, 1993.




This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
R Bhidayasiri and D D Truong
Chorea and related disorders
Postgrad. Med. J., September 1, 2004; 80(947): 527 - 534.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
A R. o. t. ANPA Committee on Research, E. C. Lauterbach, J. L. Cummings, J. Duffy, C. E. Coffey, D. Kaufer, M. Lovell, P. Malloy, A. Reeve, D. R. Royall, et al.
Neuropsychiatric Correlates and Treatment of Lenticulostriatal Diseases: A Review of the Literature and Overview of Research Opportunities in Huntington's, Wilson's, and Fahr's Diseases
J Neuropsychiatry Clin Neurosci, August 1, 1998; 10(3): 249 - 266.
[Abstract] [Full Text]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
J P P van Vugt, S Siesling, M Vergeer, E A van der Velde, and R A C Roos
Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study
J. Neurol. Neurosurg. Psychiatry, July 1, 1997; 63(1): 35 - 39.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by AAN Enterprises, Inc.